Cao Ziwen, Liu Xing, Yan Jun
Beijing Institute of Brain Disorders, Laboratory of Brain Disorders, Ministry of Science and Technology, Collaborative Innovation Center for Brain Disorders, Capital Medical University, Beijing, China.
Department of Neuropathology, Beijing Neurosurgical Institute, Beijing, China.
Front Oncol. 2024 Nov 19;14:1447113. doi: 10.3389/fonc.2024.1447113. eCollection 2024.
The CD16A protein encoding gene FcγRIIIa () and its potential ligand Fibrinogen-like protein 2 () are involved in various cell physiological activities on the extracellular surface. Aberrant expression of these genes has been linked to tumorigenesis.
To assess the prognostic significance of and transcription expression in glioma and explore their roles in glioma initiation and progression, we utilized multiple online databases, including TCGA, GEPIA, CGGA, cBioPortal, TISCH, LinkedOmics, Ivy Glioblastoma Atlas Project, and Human Protein Atlas.
Our analysis revealed that and expression was significantly correlated with clinical variables such as age, tumor type, WHO grade, histology, IDH-1 mutation, and 1p19q status. A strong correlation was also observed between the transcriptional expression levels of and . High expression of both genes predicted poor prognosis in primary and recurrent glioma patients, particularly those with lower grade gliomas. Cox regression analysis further confirmed that elevated expression of and were independent prognostic factors for shorter overall survival in glioma patients. Gene co-expression network analysis suggested that , , and their co-expressed genes were involved in inflammatory activities and tumor-related signaling pathways. Additionally, tissue microarrays from glioma patients at Tiantan Hospital showed significantly higher protein expression in high-grade gliomas compared to low-grade gliomas.
In conclusion, our findings suggest that and could serve as promising prognostic biomarkers and potential therapeutic targets for glioma patients.
编码CD16A蛋白的基因FcγRIIIa()及其潜在配体纤维蛋白原样蛋白2()参与细胞外表面的各种细胞生理活动。这些基因的异常表达与肿瘤发生有关。
为了评估FcγRIIIa和FGL2转录表达在胶质瘤中的预后意义,并探索它们在胶质瘤起始和进展中的作用,我们利用了多个在线数据库,包括TCGA、GEPIA、CGGA、cBioPortal、TISCH、LinkedOmics、Ivy胶质母细胞瘤图谱项目和人类蛋白质图谱。
我们的分析表明,FcγRIIIa和FGL2的表达与年龄、肿瘤类型、世界卫生组织分级、组织学、异柠檬酸脱氢酶-1(IDH-1)突变和1p19q状态等临床变量显著相关。FcγRIIIa和FGL2的转录表达水平之间也观察到强相关性。这两个基因的高表达预示着原发性和复发性胶质瘤患者的预后不良,尤其是低级别胶质瘤患者。Cox回归分析进一步证实,FcγRIIIa和FGL2的表达升高是胶质瘤患者总生存期较短的独立预后因素。基因共表达网络分析表明,FcγRIIIa、FGL2及其共表达基因参与炎症活动和肿瘤相关信号通路。此外,天坛医院胶质瘤患者的组织芯片显示,高级别胶质瘤中FcγRIIIa蛋白表达明显高于低级别胶质瘤。
总之,我们的研究结果表明,FcγRIIIa和FGL2可作为有前景的预后生物标志物和胶质瘤患者的潜在治疗靶点。